The use of hydroxyethyldimethyldihydropyrimidine to improve regeneration processes in a postoperative wound after sectoral resection of the breast

Abstract

Background. Partial mastectomy is the method of choice for the surgical treatment of benign neoplasms (BN) of the breast. The drawback of this technique is the occurrence of residual cavities with the accumulation of serous and hemorrhagic exudate, promoting inflammation. Hydroxyethyl dimethyldihydropyrimidine (Ximedon) in the postoperative treatment improves the healing and overall treatment outcomes. Materials and methods. The study included 101 patients. All of them had a partial mastectomy for the BN. The study patients received different pharmacotherapy in the postoperative period. They were divided into two groups depending on the use of hydroxyethyl dimethyldihydropyrimidine. Group 1 included 52 (51.5%) patients who received hydroxyethyl dimethyldihydropyrimidine 2 hours before surgery and 0.5 g on days 1 to 7 in the postoperative period. Group 2 included 49 (48.5%) patients who had not received hydroxyethyl dimethyldihydropyrimidine. Results. Analysis of treatment outcomes showed that in group 1 patients receiving hydroxyethyl dimethyldihydropyrimidine, the overall treatment results were better. Therefore, hydroxyethyldimethyldihydropyrimidine improved overall treatment outcomes and increased patients' quality of life in the postoperative period. Conclusion. The use of hydroxyethyldimethyldihydropyrimidine in the postoperative period, which has a protective effect at the cellular level due to membrane-stabilizing, antioxidant, adaptogenic, and antibacterial properties, is promising and improves wound healing, thus improving the overall results of surgical treatment of breast BNs.